What's happening
This bill prohibits the use of step therapy protocols for medically necessary prescription drugs in several therapeutic classes, including non-formulary drugs.
Why it matters
Improves patient access to critical medications. By exempting several key therapeutic classes from step therapy protocols, the bill ensures patients with serious or complex conditions (like cancer, neurological disorders, and autoimmune diseases) can access the medications their doctors deem most appropriate without first trying and failing on insurer-preferred drugs.
Limits insurance company control over treatment decisions. The bill reduces the influence of insurance-mandated treatment sequences, allowing clinicians greater discretion in prescribing the best available treatments based on individual patient needs rather than insurer cost-containment strategies.
Includes non-formulary drugs for added flexibility. By specifically including non-formulary drugs, the bill broadens the range of medications available to patients, which is particularly important for those who may not respond to standard treatments or who require specialized care.
Potentially reduces delays and complications in care. By bypassing step therapy requirements for these conditions, the legislation may help prevent unnecessary health complications, reduce administrative burdens, and speed up the initiation of effective therapies for patients with urgent or complex medical needs.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Protect Medically Needed Prescriptions
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Protect Medically Necessary Prescriptions
In Assembly Committee · Insurance · Sponsor John T. McDonald III
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
8193
IN SENATE
February 1, 2022
Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance
AN ACT to amend the insurance law and the public health law, in relation to protecting certain therapeutic classes from step therapy
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding a new paragraph 14 to read as follows:
(14) When establishing a step therapy protocol, a utilization review agent shall ensure that such protocol shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
§ 2. Section 4902 of the public health law is amended by adding a new subdivision 5 to read as follows:
5. When establishing a step therapy protocol, a utilization review agent shall ensure that such protocol shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
§ 3. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14452-01-2
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law and the public health law, in relation to protecting certain therapeutic classes from step therapy
Purpose or general idea of bill
The purpose of this bill is to prevent plans from implementing step therapy policies for certain progressive diseases.
Summary of provisions
Section one amends section 4902 of the insurance law to prohibit a utilization review agent from applying a step therapy protocol to medically necessary prescription drugs in dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
Section two amends section 4902 of the public health law to reflect the same requirement as section one.
Section three requires that this act shall take effect immediately.
Justification
Step therapy interferes with the prescriber-patient relationship and delays access to necessary care, which can negatively impact patients' health. This is especially true for those with progressive diseases who require timely access to their prescribed treatment to avoid advancing the condition and potentially causing irreversible harm.
Prior legislative history
New Bill
Fiscal implications
None
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.